14325-36-1

Basic information

• Product Name: BZ-CIT-OME
• Synonyms: BZ-CIT-OME;BZ-CITRULLINE-OME;BZO-CIT-OME;BZ-ORN(CARBAMOYL)-OME;BENZOYL-L-CITRULLINE METHYL ESTER;N-ALPHA-BENZOYL-L-CITRULLINE METHYL ESTER;N-Benzoyl-L-citrulline methyl ester;methyl N5-(aminocarbonyl)-N2-benzoyl-L-ornithine
• CAS NO: 14325-36-1
• Molecular Formula: C₁₄H₁₉N₃O₄
• Molecular Weight: 293.32
• EINECS: 238-273-5
• Mol File: 14325-36-1.mol

Chemical Properties

• Boiling Point: 533°Cat760mmHg
• Flash Point: 276.1°C
• Appearance: /
• Density: 1.21g/cm³
• Vapor Pressure: 1.94E-11mmHg at 25°C
• Refractive Index: 1.544
• Storage Temp.: 2-8°C
• CAS DataBase Reference: BZ-CIT-OME(CAS DataBase Reference)
• NIST Chemistry Reference: BZ-CIT-OME(14325-36-1)
• EPA Substance Registry System: BZ-CIT-OME(14325-36-1)

Safety Data

• Hazardous Substances Data: 14325-36-1(Hazardous Substances Data)

Usage

Chemical Properties

White powder

InChI:InChI=1/C14H19N3O4/c1-21-13(19)11(8-5-9-16-14(15)20)17-12(18)10-6-3-2-4-7-10/h2-4,6-7,11H,5,8-9H2,1H3,(H,17,18)(H3,15,16,20)/t11-/m0/s1

Upstream product

• 17966-71-1 N^α-benzoyl-L-ornithine 
• 51-79-6 urethane 
• 67-56-1 methanol 
• 10334-68-6 N^α-benzoyl-L-citrulline 
• 125735-07-1 N^α-benzoyl-N^δ-cyanoornithine methyl ester 
• 32213-95-9 DL-aspartic acid dimethyl ester hydrochloride 

Downstream Products

• 10537-27-6 Bz-Cit-NH2 
• 125735-07-1 N^α-benzoyl-N^δ-cyanoornithine methyl ester 
• 96955-27-0 N^α-benzoylarginine methyl ester hydrochloride 
• 125735-08-2 (N^α-benzoylarginino)succinic acid trimethyl ester 

Relevant articles and documents

METHOD OF TREATMENT AND PREVENTION OF NITRIC OXIDE DEFICIENCY-RELATED DISORDERS WITH CITRULLINE AND CITRULLINE DERIVATIVES

The invention provides methods for control, management, treatment and prevention of conditions related to nitric oxide deficiency such as hypertension, cardiovascular disease, osteoporosis, diabetes mellitus, preeclampsia HELLP, syndrome and fetal growth retardation; uterine contractility disorders such as preterm labor and dysmenorrhea, cervical dystocia, infertility and early pregnancy loss; male impotence; urinary incontinence; intestinal tract disorders (e.g. altered motility and pyloric stenosis), respiratory system diseases (e.g. asthma, neonatal respiratory distress syndrome, pulmonary hypertension, and adult respiratory distress syndrome); inflammatory diseases (e.g. acute inflammation, resistance to infection, SLE-lupus, anaphylactic reaction, allograft rejection); Alzheimer's disease, stroke, growth hormone disorders, and behavior changes; dermatological conditions such as atopic eczema, topical hair loss, and burn injury; by administering citrulline or a citrulline analogue, optionally in combination with other enhancing or modulating agents, e.g., an estrogenic, partial estrogenic, progestagenic, or androgenic agent, and pharmaceutical preparations for such uses.

Urea cycle: Chemical simulation of arginine biosynthesis

We have successfully simulated the salient features of the urea cycle. In this effort an appropriately protected ornithine was transformed to citrulline, via use of a novel amide transfer reagent; the citrulline, in turn, was converted into argininosuccinate which necessitated a new activation procedure to enable acceptance of dimethyl aspartate. Fragmentation of argininosuccinate under carefully controlled conditions afforded arginine. The final step in the cycle, namely, the hydrolysis of arginine to urea and ornithine, has already been accomplished. Amino group transfer from aspartate has also been demonstrated in the conversion of hypoxanthine to adenine.